Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunotherapy Consolidation in Synchronous Oligo-metastatic NSCLC
NCT06219317Phase 2Active, not recruiting
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Jan 2025
- Primary completion
- Jan 2030
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Engineered Antibody Formats
- Countries
- 5
01
Overview
A Phase 2 trial of cemiplimab in non-small cell lung cancer (NSCLC), sponsored by European Organisation for Research and Treatment of Cancer. Started Jan 2025; status: active, not recruiting.
02
Drugs
cemiplimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06219317.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06219317.